Skip to main content
. 2018 Jun 14;9(13):2380–2388. doi: 10.7150/jca.22925

Table 2.

Univariate and multivariate analyses of prognostic factors for overall survival in HCC patients who had undergone TACE in the present study.

Variable Univariate Multivariate
Log-rank χ2 P value B SE HR 95% CI P value
Age, years (> 50/≤ 50) 1.885 0.170
Ascites (yes/no) 0.719 0.396
Laboratory parameters
ALP, U/L (> 200/≤ 200) 0.952 0.329
ALB, (> 36/≤ 36) 2.039 0.153
AFP, ng/dL (> 400/≤ 400) 6.492 0.011* ND
BUN, mmol/L (> 8.9/≤ 8.9) 3.368 0.066
TBIL, mg/dL (≥ 3/< 3) 0.128 0.721
TNM-T category 12.369 0.006*
1 ND
2
3
4
PVTT (yes/no) 30.412 < 0.001* 0.635 0.133 1.887 1.455 to 2.448 < 0.001
Lymph node metastasis (yes/no) 0.611 0.435
Distant metastasis (yes/no) 13.941 < 0.001* 0.646 0.218 1.908 1.245 to 2.927 0.003
Antivirus treatments (yes/no) 0.202 0.653
Times of TACE (> 2/≤ 2) 6.863 0.009* 0.385 0.133 1.470 1.133 to 1.905 0.004

AFP: alpha fetoprotein; BUN: blood urea nitrogen; ALB: albumin; TBIL: total bilirubin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; ALBI: albumin-bilirubin grade; TNM: tumor-node-metastasis; TACE: transcatheter arterial chemoembolization; PVTT: portal vein tumor thrombus; ND: not detected. * Variables with P value less than 0.05 were entered into multivariate analysis.